nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ABCG2—epilepsy syndrome	0.0672	0.31	CbGaD
Imatinib—CYP2C19—epilepsy syndrome	0.0529	0.244	CbGaD
Imatinib—CA3—Lacosamide—epilepsy syndrome	0.0445	0.0883	CbGbCtD
Imatinib—CYP2D6—epilepsy syndrome	0.0392	0.181	CbGaD
Imatinib—CA3—Acetazolamide—epilepsy syndrome	0.0307	0.0608	CbGbCtD
Imatinib—ALB—epilepsy syndrome	0.0293	0.135	CbGaD
Imatinib—CA3—Zonisamide—epilepsy syndrome	0.0284	0.0562	CbGbCtD
Imatinib—ABCB1—epilepsy syndrome	0.028	0.129	CbGaD
Imatinib—CA14—Lacosamide—epilepsy syndrome	0.0185	0.0367	CbGbCtD
Imatinib—CA6—Lacosamide—epilepsy syndrome	0.0176	0.0348	CbGbCtD
Imatinib—CA9—Lacosamide—epilepsy syndrome	0.0131	0.0261	CbGbCtD
Imatinib—CA14—Acetazolamide—epilepsy syndrome	0.0127	0.0252	CbGbCtD
Imatinib—CA1—Lacosamide—epilepsy syndrome	0.0123	0.0244	CbGbCtD
Imatinib—CA6—Acetazolamide—epilepsy syndrome	0.0121	0.024	CbGbCtD
Imatinib—CA14—Zonisamide—epilepsy syndrome	0.0118	0.0234	CbGbCtD
Imatinib—CA6—Zonisamide—epilepsy syndrome	0.0112	0.0222	CbGbCtD
Imatinib—CA2—Lacosamide—epilepsy syndrome	0.0106	0.0211	CbGbCtD
Imatinib—CA7—Acetazolamide—epilepsy syndrome	0.0105	0.0209	CbGbCtD
Imatinib—CA7—Zonisamide—epilepsy syndrome	0.00975	0.0193	CbGbCtD
Imatinib—CA9—Acetazolamide—epilepsy syndrome	0.00904	0.0179	CbGbCtD
Imatinib—CA12—Acetazolamide—epilepsy syndrome	0.00904	0.0179	CbGbCtD
Imatinib—CA1—Acetazolamide—epilepsy syndrome	0.00846	0.0168	CbGbCtD
Imatinib—CA9—Zonisamide—epilepsy syndrome	0.00837	0.0166	CbGbCtD
Imatinib—CA12—Zonisamide—epilepsy syndrome	0.00837	0.0166	CbGbCtD
Imatinib—CA6—Topiramate—epilepsy syndrome	0.00815	0.0162	CbGbCtD
Imatinib—CA1—Zonisamide—epilepsy syndrome	0.00783	0.0155	CbGbCtD
Imatinib—CA2—Acetazolamide—epilepsy syndrome	0.00731	0.0145	CbGbCtD
Imatinib—CA7—Topiramate—epilepsy syndrome	0.0071	0.0141	CbGbCtD
Imatinib—CA2—Zonisamide—epilepsy syndrome	0.00676	0.0134	CbGbCtD
Imatinib—CA12—Topiramate—epilepsy syndrome	0.0061	0.0121	CbGbCtD
Imatinib—CA9—Topiramate—epilepsy syndrome	0.0061	0.0121	CbGbCtD
Imatinib—CA1—Topiramate—epilepsy syndrome	0.0057	0.0113	CbGbCtD
Imatinib—CA2—Topiramate—epilepsy syndrome	0.00493	0.00977	CbGbCtD
Imatinib—ALB—Oxcarbazepine—epilepsy syndrome	0.00477	0.00946	CbGbCtD
Imatinib—ALB—Fosphenytoin—epilepsy syndrome	0.00417	0.00827	CbGbCtD
Imatinib—SLC22A1—Midazolam—epilepsy syndrome	0.00403	0.008	CbGbCtD
Imatinib—CYP3A5—Oxcarbazepine—epilepsy syndrome	0.00384	0.0076	CbGbCtD
Imatinib—ALB—Clonazepam—epilepsy syndrome	0.00377	0.00748	CbGbCtD
Imatinib—CYP3A7—Carbamazepine—epilepsy syndrome	0.00321	0.00637	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Carbamazepine—epilepsy syndrome	0.00321	0.00637	CbGbCtD
Imatinib—CYP2C19—Oxcarbazepine—epilepsy syndrome	0.00309	0.00613	CbGbCtD
Imatinib—ALB—Rufinamide—epilepsy syndrome	0.00308	0.0061	CbGbCtD
Imatinib—PTGS1—Diazepam—epilepsy syndrome	0.00304	0.00603	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Phenytoin—epilepsy syndrome	0.00288	0.00571	CbGbCtD
Imatinib—CYP3A7—Phenytoin—epilepsy syndrome	0.00288	0.00571	CbGbCtD
Imatinib—CYP2C19—Trimethadione—epilepsy syndrome	0.00288	0.0057	CbGbCtD
Imatinib—CYP2C19—Felbamate—epilepsy syndrome	0.00288	0.0057	CbGbCtD
Imatinib—ABCB1—Levetiracetam—epilepsy syndrome	0.00273	0.00541	CbGbCtD
Imatinib—CYP2C19—Fosphenytoin—epilepsy syndrome	0.0027	0.00536	CbGbCtD
Imatinib—ALB—Phenytoin—epilepsy syndrome	0.00269	0.00533	CbGbCtD
Imatinib—CYP3A7—Phenobarbital—epilepsy syndrome	0.00257	0.00509	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Phenobarbital—epilepsy syndrome	0.00257	0.00509	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Midazolam—epilepsy syndrome	0.00253	0.00502	CbGbCtD
Imatinib—CYP3A7—Midazolam—epilepsy syndrome	0.00253	0.00502	CbGbCtD
Imatinib—ALB—Propofol—epilepsy syndrome	0.00251	0.00497	CbGbCtD
Imatinib—CYP3A7—Diazepam—epilepsy syndrome	0.00243	0.00482	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Diazepam—epilepsy syndrome	0.00243	0.00482	CbGbCtD
Imatinib—CYP3A5—Carbamazepine—epilepsy syndrome	0.00241	0.00478	CbGbCtD
Imatinib—PTGS1—Valproic Acid—epilepsy syndrome	0.0024	0.00475	CbGbCtD
Imatinib—CYP2C9—Trimethadione—epilepsy syndrome	0.00239	0.00474	CbGbCtD
Imatinib—CYP2C19—Clobazam—epilepsy syndrome	0.00234	0.00465	CbGbCtD
Imatinib—ALB—Diazepam—epilepsy syndrome	0.00227	0.0045	CbGbCtD
Imatinib—CYP2C9—Fosphenytoin—epilepsy syndrome	0.00225	0.00446	CbGbCtD
Imatinib—CYP3A5—Phenytoin—epilepsy syndrome	0.00216	0.00428	CbGbCtD
Imatinib—CYP2C19—Carbamazepine—epilepsy syndrome	0.00194	0.00385	CbGbCtD
Imatinib—CYP3A5—Phenobarbital—epilepsy syndrome	0.00193	0.00382	CbGbCtD
Imatinib—CYP3A5—Midazolam—epilepsy syndrome	0.0019	0.00376	CbGbCtD
Imatinib—ABCB1—Clobazam—epilepsy syndrome	0.00189	0.00375	CbGbCtD
Imatinib—CYP3A5—Diazepam—epilepsy syndrome	0.00183	0.00362	CbGbCtD
Imatinib—ABCB1—Lamotrigine—epilepsy syndrome	0.00182	0.00361	CbGbCtD
Imatinib—CYP2C19—Primidone—epilepsy syndrome	0.00181	0.0036	CbGbCtD
Imatinib—CA6—ear—epilepsy syndrome	0.0018	0.0425	CbGeAlD
Imatinib—CYP1A2—Carbamazepine—epilepsy syndrome	0.00179	0.00355	CbGbCtD
Imatinib—CYP2C19—Phenytoin—epilepsy syndrome	0.00174	0.00345	CbGbCtD
Imatinib—CA3—ear—epilepsy syndrome	0.0017	0.0402	CbGeAlD
Imatinib—CYP1A2—Primidone—epilepsy syndrome	0.00167	0.00332	CbGbCtD
Imatinib—CYP2C19—Propofol—epilepsy syndrome	0.00163	0.00322	CbGbCtD
Imatinib—CYP2C9—Carbamazepine—epilepsy syndrome	0.00162	0.0032	CbGbCtD
Imatinib—ABCB1—Carbamazepine—epilepsy syndrome	0.00157	0.00311	CbGbCtD
Imatinib—CYP2C19—Phenobarbital—epilepsy syndrome	0.00155	0.00308	CbGbCtD
Imatinib—CYP2C9—Primidone—epilepsy syndrome	0.00151	0.00299	CbGbCtD
Imatinib—CYP1A2—Propofol—epilepsy syndrome	0.0015	0.00297	CbGbCtD
Imatinib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0015	0.00297	CbGbCtD
Imatinib—CYP2C19—Diazepam—epilepsy syndrome	0.00147	0.00292	CbGbCtD
Imatinib—CYP2C9—Phenytoin—epilepsy syndrome	0.00145	0.00287	CbGbCtD
Imatinib—CYP3A5—Valproic Acid—epilepsy syndrome	0.00144	0.00285	CbGbCtD
Imatinib—CYP2C19—Zonisamide—epilepsy syndrome	0.00144	0.00285	CbGbCtD
Imatinib—CYP1A2—Phenobarbital—epilepsy syndrome	0.00143	0.00284	CbGbCtD
Imatinib—ABCB1—Phenytoin—epilepsy syndrome	0.00141	0.00279	CbGbCtD
Imatinib—CYP3A4—Felbamate—epilepsy syndrome	0.00139	0.00276	CbGbCtD
Imatinib—CYP3A4—Trimethadione—epilepsy syndrome	0.00139	0.00276	CbGbCtD
Imatinib—CYP1A2—Diazepam—epilepsy syndrome	0.00136	0.00269	CbGbCtD
Imatinib—CYP2C9—Propofol—epilepsy syndrome	0.00135	0.00268	CbGbCtD
Imatinib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00131	0.00259	CbGbCtD
Imatinib—CYP2C9—Phenobarbital—epilepsy syndrome	0.00129	0.00256	CbGbCtD
Imatinib—ABCB1—Phenobarbital—epilepsy syndrome	0.00125	0.00248	CbGbCtD
Imatinib—ABCB1—Midazolam—epilepsy syndrome	0.00124	0.00245	CbGbCtD
Imatinib—CYP2D6—Propofol—epilepsy syndrome	0.00124	0.00245	CbGbCtD
Imatinib—CYP2C9—Diazepam—epilepsy syndrome	0.00122	0.00243	CbGbCtD
Imatinib—ABCB1—Diazepam—epilepsy syndrome	0.00119	0.00236	CbGbCtD
Imatinib—CYP3A4—Clonazepam—epilepsy syndrome	0.00118	0.00234	CbGbCtD
Imatinib—CYP2C19—Valproic Acid—epilepsy syndrome	0.00116	0.0023	CbGbCtD
Imatinib—CYP3A4—Clobazam—epilepsy syndrome	0.00113	0.00225	CbGbCtD
Imatinib—CYP1A2—Valproic Acid—epilepsy syndrome	0.00107	0.00212	CbGbCtD
Imatinib—CYP2C19—Topiramate—epilepsy syndrome	0.00105	0.00208	CbGbCtD
Imatinib—CYP2C9—Valproic Acid—epilepsy syndrome	0.000965	0.00191	CbGbCtD
Imatinib—CYP3A4—Rufinamide—epilepsy syndrome	0.000964	0.00191	CbGbCtD
Imatinib—CYP3A4—Carbamazepine—epilepsy syndrome	0.000939	0.00186	CbGbCtD
Imatinib—CYP3A4—Primidone—epilepsy syndrome	0.000877	0.00174	CbGbCtD
Imatinib—CYP3A4—Phenytoin—epilepsy syndrome	0.000842	0.00167	CbGbCtD
Imatinib—CYP3A4—Propofol—epilepsy syndrome	0.000786	0.00156	CbGbCtD
Imatinib—ABCA3—telencephalon—epilepsy syndrome	0.000751	0.0177	CbGeAlD
Imatinib—CYP3A4—Acetazolamide—epilepsy syndrome	0.000751	0.00149	CbGbCtD
Imatinib—CYP3A4—Phenobarbital—epilepsy syndrome	0.000751	0.00149	CbGbCtD
Imatinib—CYP3A4—Midazolam—epilepsy syndrome	0.00074	0.00147	CbGbCtD
Imatinib—CYP3A4—Diazepam—epilepsy syndrome	0.000712	0.00141	CbGbCtD
Imatinib—CYP3A4—Zonisamide—epilepsy syndrome	0.000695	0.00138	CbGbCtD
Imatinib—DDR1—telencephalon—epilepsy syndrome	0.000693	0.0164	CbGeAlD
Imatinib—NTRK1—midbrain—epilepsy syndrome	0.000682	0.0161	CbGeAlD
Imatinib—Ponatinib—TEK—epilepsy syndrome	0.000624	0.183	CrCbGaD
Imatinib—NQO2—hindbrain—epilepsy syndrome	0.000618	0.0146	CbGeAlD
Imatinib—ABCA3—medulla oblongata—epilepsy syndrome	0.00059	0.0139	CbGeAlD
Imatinib—Ponatinib—RET—epilepsy syndrome	0.00058	0.17	CrCbGaD
Imatinib—CYP3A4—Valproic Acid—epilepsy syndrome	0.000561	0.00111	CbGbCtD
Imatinib—SLC22A1—ganglion—epilepsy syndrome	0.000545	0.0129	CbGeAlD
Imatinib—DDR1—medulla oblongata—epilepsy syndrome	0.000545	0.0129	CbGeAlD
Imatinib—ABCA3—midbrain—epilepsy syndrome	0.000539	0.0127	CbGeAlD
Imatinib—ABCA3—spinal cord—epilepsy syndrome	0.000526	0.0124	CbGeAlD
Imatinib—CYP3A4—Topiramate—epilepsy syndrome	0.000506	0.001	CbGbCtD
Imatinib—DDR1—midbrain—epilepsy syndrome	0.000498	0.0118	CbGeAlD
Imatinib—SLC47A1—hindbrain—epilepsy syndrome	0.000495	0.0117	CbGeAlD
Imatinib—KIT—hindbrain—epilepsy syndrome	0.000493	0.0116	CbGeAlD
Imatinib—DDR1—spinal cord—epilepsy syndrome	0.000486	0.0115	CbGeAlD
Imatinib—ABCA3—head—epilepsy syndrome	0.000468	0.011	CbGeAlD
Imatinib—Nilotinib—TEK—epilepsy syndrome	0.000461	0.135	CrCbGaD
Imatinib—CA3—forebrain—epilepsy syndrome	0.000444	0.0105	CbGeAlD
Imatinib—ABCA3—nervous system—epilepsy syndrome	0.000443	0.0105	CbGeAlD
Imatinib—ABL1—hindbrain—epilepsy syndrome	0.000429	0.0101	CbGeAlD
Imatinib—PIP4K2C—telencephalon—epilepsy syndrome	0.000428	0.0101	CbGeAlD
Imatinib—ABCA3—central nervous system—epilepsy syndrome	0.000427	0.0101	CbGeAlD
Imatinib—ABCA3—cerebellum—epilepsy syndrome	0.000417	0.00985	CbGeAlD
Imatinib—CA3—telencephalon—epilepsy syndrome	0.000409	0.00964	CbGeAlD
Imatinib—DDR1—cerebellum—epilepsy syndrome	0.000385	0.00909	CbGeAlD
Imatinib—CA14—telencephalon—epilepsy syndrome	0.000371	0.00876	CbGeAlD
Imatinib—NQO2—brainstem—epilepsy syndrome	0.000354	0.00836	CbGeAlD
Imatinib—HIPK4—brain—epilepsy syndrome	0.000343	0.00809	CbGeAlD
Imatinib—PDGFRA—forebrain—epilepsy syndrome	0.000341	0.00805	CbGeAlD
Imatinib—ABCA3—brain—epilepsy syndrome	0.000339	0.008	CbGeAlD
Imatinib—PIP4K2C—medulla oblongata—epilepsy syndrome	0.000336	0.00794	CbGeAlD
Imatinib—Ponatinib—SRC—epilepsy syndrome	0.000324	0.0952	CrCbGaD
Imatinib—CA7—midbrain—epilepsy syndrome	0.00032	0.00755	CbGeAlD
Imatinib—CA12—forebrain—epilepsy syndrome	0.000315	0.00743	CbGeAlD
Imatinib—NQO2—telencephalon—epilepsy syndrome	0.000314	0.00742	CbGeAlD
Imatinib—PDGFRA—telencephalon—epilepsy syndrome	0.000313	0.0074	CbGeAlD
Imatinib—DDR1—brain—epilepsy syndrome	0.000313	0.00738	CbGeAlD
Imatinib—PIP4K2C—midbrain—epilepsy syndrome	0.000307	0.00725	CbGeAlD
Imatinib—Ponatinib—KDR—epilepsy syndrome	0.000305	0.0895	CrCbGaD
Imatinib—CSF1R—forebrain—epilepsy syndrome	0.0003	0.00708	CbGeAlD
Imatinib—PIP4K2C—spinal cord—epilepsy syndrome	0.0003	0.00708	CbGeAlD
Imatinib—PTGS1—ganglion—epilepsy syndrome	0.000297	0.00702	CbGeAlD
Imatinib—CA2—hindbrain—epilepsy syndrome	0.000292	0.00689	CbGeAlD
Imatinib—CA14—medulla oblongata—epilepsy syndrome	0.000291	0.00688	CbGeAlD
Imatinib—CA12—telencephalon—epilepsy syndrome	0.000289	0.00683	CbGeAlD
Imatinib—SLC47A1—brainstem—epilepsy syndrome	0.000284	0.0067	CbGeAlD
Imatinib—KIT—brainstem—epilepsy syndrome	0.000282	0.00667	CbGeAlD
Imatinib—Buclizine—CHRM1—epilepsy syndrome	0.000282	0.0829	CrCbGaD
Imatinib—Nilotinib—CA4—epilepsy syndrome	0.000276	0.081	CrCbGaD
Imatinib—CSF1R—telencephalon—epilepsy syndrome	0.000276	0.00651	CbGeAlD
Imatinib—CA6—head—epilepsy syndrome	0.000269	0.00634	CbGeAlD
Imatinib—PIP4K2C—head—epilepsy syndrome	0.000266	0.00629	CbGeAlD
Imatinib—CA14—midbrain—epilepsy syndrome	0.000266	0.00629	CbGeAlD
Imatinib—CA14—spinal cord—epilepsy syndrome	0.00026	0.00614	CbGeAlD
Imatinib—CA3—head—epilepsy syndrome	0.000254	0.006	CbGeAlD
Imatinib—PIP4K2C—nervous system—epilepsy syndrome	0.000253	0.00596	CbGeAlD
Imatinib—ABL2—cerebellum—epilepsy syndrome	0.000251	0.00593	CbGeAlD
Imatinib—KIT—telencephalon—epilepsy syndrome	0.000251	0.00591	CbGeAlD
Imatinib—CA1—forebrain—epilepsy syndrome	0.000249	0.00588	CbGeAlD
Imatinib—CA7—cerebellum—epilepsy syndrome	0.000247	0.00584	CbGeAlD
Imatinib—NQO2—medulla oblongata—epilepsy syndrome	0.000247	0.00583	CbGeAlD
Imatinib—ABL1—brainstem—epilepsy syndrome	0.000246	0.0058	CbGeAlD
Imatinib—PDGFRB—telencephalon—epilepsy syndrome	0.000245	0.00578	CbGeAlD
Imatinib—PIP4K2C—central nervous system—epilepsy syndrome	0.000243	0.00574	CbGeAlD
Imatinib—CA3—nervous system—epilepsy syndrome	0.000241	0.00569	CbGeAlD
Imatinib—PIP4K2C—cerebellum—epilepsy syndrome	0.000238	0.00561	CbGeAlD
Imatinib—CA3—central nervous system—epilepsy syndrome	0.000232	0.00548	CbGeAlD
Imatinib—CA1—telencephalon—epilepsy syndrome	0.000229	0.00541	CbGeAlD
Imatinib—SLC22A1—forebrain—epilepsy syndrome	0.000229	0.0054	CbGeAlD
Imatinib—NQO2—midbrain—epilepsy syndrome	0.000226	0.00533	CbGeAlD
Imatinib—NQO2—spinal cord—epilepsy syndrome	0.00022	0.0052	CbGeAlD
Imatinib—PDGFRA—spinal cord—epilepsy syndrome	0.00022	0.00518	CbGeAlD
Imatinib—ABL1—telencephalon—epilepsy syndrome	0.000218	0.00515	CbGeAlD
Imatinib—CA9—cerebellum—epilepsy syndrome	0.000217	0.00513	CbGeAlD
Imatinib—CSF1R—medulla oblongata—epilepsy syndrome	0.000217	0.00512	CbGeAlD
Imatinib—SLC22A1—telencephalon—epilepsy syndrome	0.00021	0.00496	CbGeAlD
Imatinib—CA14—cerebellum—epilepsy syndrome	0.000206	0.00486	CbGeAlD
Imatinib—ABL2—brain—epilepsy syndrome	0.000204	0.00482	CbGeAlD
Imatinib—CA7—brain—epilepsy syndrome	0.000201	0.00474	CbGeAlD
Imatinib—CSF1R—midbrain—epilepsy syndrome	0.000198	0.00468	CbGeAlD
Imatinib—SLC47A1—medulla oblongata—epilepsy syndrome	0.000198	0.00467	CbGeAlD
Imatinib—KIT—medulla oblongata—epilepsy syndrome	0.000197	0.00465	CbGeAlD
Imatinib—NQO2—head—epilepsy syndrome	0.000196	0.00462	CbGeAlD
Imatinib—PDGFRA—head—epilepsy syndrome	0.000195	0.00461	CbGeAlD
Imatinib—CSF1R—spinal cord—epilepsy syndrome	0.000193	0.00456	CbGeAlD
Imatinib—PIP4K2C—brain—epilepsy syndrome	0.000193	0.00456	CbGeAlD
Imatinib—PDGFRB—medulla oblongata—epilepsy syndrome	0.000192	0.00454	CbGeAlD
Imatinib—NQO2—nervous system—epilepsy syndrome	0.000186	0.00438	CbGeAlD
Imatinib—CYP2D6—hindbrain—epilepsy syndrome	0.000185	0.00438	CbGeAlD
Imatinib—PDGFRA—nervous system—epilepsy syndrome	0.000185	0.00437	CbGeAlD
Imatinib—CA3—brain—epilepsy syndrome	0.000184	0.00435	CbGeAlD
Imatinib—CA12—head—epilepsy syndrome	0.00018	0.00425	CbGeAlD
Imatinib—KIT—midbrain—epilepsy syndrome	0.00018	0.00425	CbGeAlD
Imatinib—NQO2—central nervous system—epilepsy syndrome	0.000179	0.00422	CbGeAlD
Imatinib—PDGFRA—central nervous system—epilepsy syndrome	0.000178	0.00421	CbGeAlD
Imatinib—SLC47A1—spinal cord—epilepsy syndrome	0.000177	0.00417	CbGeAlD
Imatinib—PDGFRB—midbrain—epilepsy syndrome	0.000176	0.00415	CbGeAlD
Imatinib—KIT—spinal cord—epilepsy syndrome	0.000176	0.00414	CbGeAlD
Imatinib—NQO2—cerebellum—epilepsy syndrome	0.000175	0.00412	CbGeAlD
Imatinib—PDGFRA—cerebellum—epilepsy syndrome	0.000174	0.00411	CbGeAlD
Imatinib—CSF1R—head—epilepsy syndrome	0.000172	0.00406	CbGeAlD
Imatinib—PDGFRB—spinal cord—epilepsy syndrome	0.000171	0.00405	CbGeAlD
Imatinib—ABL1—medulla oblongata—epilepsy syndrome	0.000171	0.00405	CbGeAlD
Imatinib—CA12—nervous system—epilepsy syndrome	0.000171	0.00403	CbGeAlD
Imatinib—CA14—brain—epilepsy syndrome	0.000167	0.00395	CbGeAlD
Imatinib—CA2—brainstem—epilepsy syndrome	0.000167	0.00395	CbGeAlD
Imatinib—CA12—central nervous system—epilepsy syndrome	0.000164	0.00388	CbGeAlD
Imatinib—CSF1R—nervous system—epilepsy syndrome	0.000163	0.00385	CbGeAlD
Imatinib—CA2—forebrain—epilepsy syndrome	0.000162	0.00381	CbGeAlD
Imatinib—ORM1—spinal cord—epilepsy syndrome	0.000161	0.0038	CbGeAlD
Imatinib—CA1—spinal cord—epilepsy syndrome	0.000161	0.00379	CbGeAlD
Imatinib—Ponatinib—ABCG2—epilepsy syndrome	0.000159	0.0468	CrCbGaD
Imatinib—SLC47A1—head—epilepsy syndrome	0.000157	0.0037	CbGeAlD
Imatinib—CSF1R—central nervous system—epilepsy syndrome	0.000157	0.0037	CbGeAlD
Imatinib—ABL1—midbrain—epilepsy syndrome	0.000157	0.0037	CbGeAlD
Imatinib—KIT—head—epilepsy syndrome	0.000156	0.00368	CbGeAlD
Imatinib—CSF1R—cerebellum—epilepsy syndrome	0.000153	0.00362	CbGeAlD
Imatinib—ABL1—spinal cord—epilepsy syndrome	0.000153	0.00361	CbGeAlD
Imatinib—PDGFRB—head—epilepsy syndrome	0.000152	0.0036	CbGeAlD
Imatinib—SLC47A1—nervous system—epilepsy syndrome	0.000149	0.00351	CbGeAlD
Imatinib—CA2—telencephalon—epilepsy syndrome	0.000149	0.00351	CbGeAlD
Imatinib—KIT—nervous system—epilepsy syndrome	0.000148	0.00349	CbGeAlD
Imatinib—PDGFRB—nervous system—epilepsy syndrome	0.000144	0.00341	CbGeAlD
Imatinib—SLC47A1—central nervous system—epilepsy syndrome	0.000143	0.00338	CbGeAlD
Imatinib—CA1—head—epilepsy syndrome	0.000143	0.00337	CbGeAlD
Imatinib—KIT—central nervous system—epilepsy syndrome	0.000142	0.00336	CbGeAlD
Imatinib—NQO2—brain—epilepsy syndrome	0.000142	0.00335	CbGeAlD
Imatinib—PDGFRA—brain—epilepsy syndrome	0.000141	0.00334	CbGeAlD
Imatinib—SLC47A1—cerebellum—epilepsy syndrome	0.00014	0.00331	CbGeAlD
Imatinib—KIT—cerebellum—epilepsy syndrome	0.000139	0.00329	CbGeAlD
Imatinib—PDGFRB—central nervous system—epilepsy syndrome	0.000139	0.00328	CbGeAlD
Imatinib—ABCG2—telencephalon—epilepsy syndrome	0.000138	0.00325	CbGeAlD
Imatinib—PDGFRB—cerebellum—epilepsy syndrome	0.000136	0.00321	CbGeAlD
Imatinib—ABL1—head—epilepsy syndrome	0.000136	0.00321	CbGeAlD
Imatinib—ORM1—nervous system—epilepsy syndrome	0.000136	0.0032	CbGeAlD
Imatinib—CA1—nervous system—epilepsy syndrome	0.000135	0.00319	CbGeAlD
Imatinib—SLC22A1—head—epilepsy syndrome	0.000131	0.00309	CbGeAlD
Imatinib—CA12—brain—epilepsy syndrome	0.000131	0.00308	CbGeAlD
Imatinib—ORM1—central nervous system—epilepsy syndrome	0.00013	0.00308	CbGeAlD
Imatinib—CA1—central nervous system—epilepsy syndrome	0.00013	0.00307	CbGeAlD
Imatinib—ABL1—nervous system—epilepsy syndrome	0.000129	0.00304	CbGeAlD
Imatinib—PTGS1—forebrain—epilepsy syndrome	0.000125	0.00295	CbGeAlD
Imatinib—CSF1R—brain—epilepsy syndrome	0.000125	0.00294	CbGeAlD
Imatinib—SLC22A1—nervous system—epilepsy syndrome	0.000124	0.00293	CbGeAlD
Imatinib—ABL1—central nervous system—epilepsy syndrome	0.000124	0.00293	CbGeAlD
Imatinib—ABL1—cerebellum—epilepsy syndrome	0.000121	0.00286	CbGeAlD
Imatinib—SLC22A1—central nervous system—epilepsy syndrome	0.00012	0.00282	CbGeAlD
Imatinib—Nilotinib—ABCG2—epilepsy syndrome	0.000118	0.0345	CrCbGaD
Imatinib—CA2—medulla oblongata—epilepsy syndrome	0.000117	0.00275	CbGeAlD
Imatinib—PTGS1—telencephalon—epilepsy syndrome	0.000115	0.00271	CbGeAlD
Imatinib—SLC47A1—brain—epilepsy syndrome	0.000114	0.00268	CbGeAlD
Imatinib—KIT—brain—epilepsy syndrome	0.000113	0.00267	CbGeAlD
Imatinib—PDGFRB—brain—epilepsy syndrome	0.00011	0.00261	CbGeAlD
Imatinib—ABCG2—medulla oblongata—epilepsy syndrome	0.000108	0.00255	CbGeAlD
Imatinib—CA2—midbrain—epilepsy syndrome	0.000107	0.00252	CbGeAlD
Imatinib—CYP2D6—brainstem—epilepsy syndrome	0.000106	0.00251	CbGeAlD
Imatinib—CA2—spinal cord—epilepsy syndrome	0.000104	0.00246	CbGeAlD
Imatinib—CA1—brain—epilepsy syndrome	0.000103	0.00244	CbGeAlD
Imatinib—CYP2D6—forebrain—epilepsy syndrome	0.000103	0.00242	CbGeAlD
Imatinib—ABCG2—midbrain—epilepsy syndrome	9.88e-05	0.00233	CbGeAlD
Imatinib—ABL1—brain—epilepsy syndrome	9.84e-05	0.00232	CbGeAlD
Imatinib—ABCG2—spinal cord—epilepsy syndrome	9.64e-05	0.00228	CbGeAlD
Imatinib—SLC22A1—brain—epilepsy syndrome	9.49e-05	0.00224	CbGeAlD
Imatinib—CYP2D6—telencephalon—epilepsy syndrome	9.43e-05	0.00223	CbGeAlD
Imatinib—Ponatinib—CYP2D6—epilepsy syndrome	9.28e-05	0.0273	CrCbGaD
Imatinib—CA2—head—epilepsy syndrome	9.25e-05	0.00218	CbGeAlD
Imatinib—ALB—brain—epilepsy syndrome	9.08e-05	0.00214	CbGeAlD
Imatinib—CA2—nervous system—epilepsy syndrome	8.77e-05	0.00207	CbGeAlD
Imatinib—CA2—central nervous system—epilepsy syndrome	8.44e-05	0.00199	CbGeAlD
Imatinib—CA2—cerebellum—epilepsy syndrome	8.25e-05	0.00195	CbGeAlD
Imatinib—PTGS1—spinal cord—epilepsy syndrome	8.04e-05	0.0019	CbGeAlD
Imatinib—ABCG2—cerebellum—epilepsy syndrome	7.64e-05	0.0018	CbGeAlD
Imatinib—ABCB1—forebrain—epilepsy syndrome	7.38e-05	0.00174	CbGeAlD
Imatinib—PTGS1—head—epilepsy syndrome	7.14e-05	0.00169	CbGeAlD
Imatinib—Nilotinib—CYP2D6—epilepsy syndrome	6.85e-05	0.0201	CrCbGaD
Imatinib—ABCB1—telencephalon—epilepsy syndrome	6.78e-05	0.0016	CbGeAlD
Imatinib—PTGS1—nervous system—epilepsy syndrome	6.77e-05	0.0016	CbGeAlD
Imatinib—CA2—brain—epilepsy syndrome	6.7e-05	0.00158	CbGeAlD
Imatinib—Ponatinib—ABCB1—epilepsy syndrome	6.63e-05	0.0195	CrCbGaD
Imatinib—PTGS1—central nervous system—epilepsy syndrome	6.52e-05	0.00154	CbGeAlD
Imatinib—ABCG2—brain—epilepsy syndrome	6.21e-05	0.00147	CbGeAlD
Imatinib—CYP2D6—head—epilepsy syndrome	5.87e-05	0.00139	CbGeAlD
Imatinib—CYP3A4—nervous system—epilepsy syndrome	5.66e-05	0.00134	CbGeAlD
Imatinib—CYP2D6—nervous system—epilepsy syndrome	5.57e-05	0.00131	CbGeAlD
Imatinib—CYP3A4—central nervous system—epilepsy syndrome	5.45e-05	0.00129	CbGeAlD
Imatinib—CYP2D6—central nervous system—epilepsy syndrome	5.36e-05	0.00127	CbGeAlD
Imatinib—ABCB1—medulla oblongata—epilepsy syndrome	5.33e-05	0.00126	CbGeAlD
Imatinib—CYP2D6—cerebellum—epilepsy syndrome	5.24e-05	0.00124	CbGeAlD
Imatinib—PTGS1—brain—epilepsy syndrome	5.18e-05	0.00122	CbGeAlD
Imatinib—Nilotinib—ABCB1—epilepsy syndrome	4.89e-05	0.0144	CrCbGaD
Imatinib—ABCB1—midbrain—epilepsy syndrome	4.87e-05	0.00115	CbGeAlD
Imatinib—ABCB1—spinal cord—epilepsy syndrome	4.75e-05	0.00112	CbGeAlD
Imatinib—CYP2D6—brain—epilepsy syndrome	4.26e-05	0.001	CbGeAlD
Imatinib—ABCB1—head—epilepsy syndrome	4.22e-05	0.000997	CbGeAlD
Imatinib—ABCB1—nervous system—epilepsy syndrome	4e-05	0.000945	CbGeAlD
Imatinib—ABCB1—central nervous system—epilepsy syndrome	3.86e-05	0.00091	CbGeAlD
Imatinib—ABCB1—cerebellum—epilepsy syndrome	3.77e-05	0.00089	CbGeAlD
Imatinib—ABCB1—brain—epilepsy syndrome	3.06e-05	0.000723	CbGeAlD
Imatinib—Diarrhoea—Clonazepam—epilepsy syndrome	2.17e-05	0.000154	CcSEcCtD
Imatinib—Anaemia—Gabapentin—epilepsy syndrome	2.17e-05	0.000154	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	2.17e-05	0.000154	CcSEcCtD
Imatinib—Hypotension—Valproic Acid—epilepsy syndrome	2.16e-05	0.000154	CcSEcCtD
Imatinib—Asthenia—Carbamazepine—epilepsy syndrome	2.16e-05	0.000154	CcSEcCtD
Imatinib—Diarrhoea—Phenytoin—epilepsy syndrome	2.16e-05	0.000153	CcSEcCtD
Imatinib—Discomfort—Pregabalin—epilepsy syndrome	2.15e-05	0.000153	CcSEcCtD
Imatinib—Nausea—Fosphenytoin—epilepsy syndrome	2.15e-05	0.000153	CcSEcCtD
Imatinib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	2.15e-05	0.000153	CcSEcCtD
Imatinib—Erythema multiforme—Topiramate—epilepsy syndrome	2.15e-05	0.000153	CcSEcCtD
Imatinib—Angioedema—Gabapentin—epilepsy syndrome	2.15e-05	0.000153	CcSEcCtD
Imatinib—Hypersensitivity—Lamotrigine—epilepsy syndrome	2.14e-05	0.000152	CcSEcCtD
Imatinib—Vomiting—Felbamate—epilepsy syndrome	2.14e-05	0.000152	CcSEcCtD
Imatinib—Dry mouth—Pregabalin—epilepsy syndrome	2.13e-05	0.000152	CcSEcCtD
Imatinib—Pruritus—Carbamazepine—epilepsy syndrome	2.13e-05	0.000151	CcSEcCtD
Imatinib—Rash—Felbamate—epilepsy syndrome	2.12e-05	0.000151	CcSEcCtD
Imatinib—Eye disorder—Topiramate—epilepsy syndrome	2.12e-05	0.000151	CcSEcCtD
Imatinib—Dermatitis—Felbamate—epilepsy syndrome	2.12e-05	0.000151	CcSEcCtD
Imatinib—Malaise—Gabapentin—epilepsy syndrome	2.12e-05	0.000151	CcSEcCtD
Imatinib—Tinnitus—Topiramate—epilepsy syndrome	2.12e-05	0.00015	CcSEcCtD
Imatinib—Vertigo—Gabapentin—epilepsy syndrome	2.11e-05	0.00015	CcSEcCtD
Imatinib—Headache—Felbamate—epilepsy syndrome	2.11e-05	0.00015	CcSEcCtD
Imatinib—Confusional state—Pregabalin—epilepsy syndrome	2.11e-05	0.00015	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	2.11e-05	0.00015	CcSEcCtD
Imatinib—Flushing—Topiramate—epilepsy syndrome	2.11e-05	0.00015	CcSEcCtD
Imatinib—Cardiac disorder—Topiramate—epilepsy syndrome	2.11e-05	0.00015	CcSEcCtD
Imatinib—Syncope—Gabapentin—epilepsy syndrome	2.11e-05	0.00015	CcSEcCtD
Imatinib—Leukopenia—Gabapentin—epilepsy syndrome	2.1e-05	0.000149	CcSEcCtD
Imatinib—Dizziness—Clonazepam—epilepsy syndrome	2.1e-05	0.000149	CcSEcCtD
Imatinib—Nausea—Vigabatrin—epilepsy syndrome	2.1e-05	0.000149	CcSEcCtD
Imatinib—Vomiting—Zonisamide—epilepsy syndrome	2.1e-05	0.000149	CcSEcCtD
Imatinib—Insomnia—Valproic Acid—epilepsy syndrome	2.09e-05	0.000149	CcSEcCtD
Imatinib—Anaphylactic shock—Pregabalin—epilepsy syndrome	2.09e-05	0.000149	CcSEcCtD
Imatinib—Oedema—Pregabalin—epilepsy syndrome	2.09e-05	0.000149	CcSEcCtD
Imatinib—Asthenia—Lamotrigine—epilepsy syndrome	2.09e-05	0.000148	CcSEcCtD
Imatinib—Dizziness—Phenytoin—epilepsy syndrome	2.09e-05	0.000148	CcSEcCtD
Imatinib—Rash—Zonisamide—epilepsy syndrome	2.08e-05	0.000148	CcSEcCtD
Imatinib—Infection—Pregabalin—epilepsy syndrome	2.08e-05	0.000148	CcSEcCtD
Imatinib—Paraesthesia—Valproic Acid—epilepsy syndrome	2.08e-05	0.000148	CcSEcCtD
Imatinib—Palpitations—Gabapentin—epilepsy syndrome	2.08e-05	0.000148	CcSEcCtD
Imatinib—Dermatitis—Zonisamide—epilepsy syndrome	2.08e-05	0.000148	CcSEcCtD
Imatinib—Dizziness—Oxcarbazepine—epilepsy syndrome	2.08e-05	0.000147	CcSEcCtD
Imatinib—Nausea—Diazepam—epilepsy syndrome	2.07e-05	0.000147	CcSEcCtD
Imatinib—Loss of consciousness—Gabapentin—epilepsy syndrome	2.06e-05	0.000147	CcSEcCtD
Imatinib—Headache—Zonisamide—epilepsy syndrome	2.06e-05	0.000147	CcSEcCtD
Imatinib—Dyspnoea—Valproic Acid—epilepsy syndrome	2.06e-05	0.000147	CcSEcCtD
Imatinib—Diarrhoea—Carbamazepine—epilepsy syndrome	2.06e-05	0.000146	CcSEcCtD
Imatinib—Angiopathy—Topiramate—epilepsy syndrome	2.06e-05	0.000146	CcSEcCtD
Imatinib—Pruritus—Lamotrigine—epilepsy syndrome	2.06e-05	0.000146	CcSEcCtD
Imatinib—Shock—Pregabalin—epilepsy syndrome	2.06e-05	0.000146	CcSEcCtD
Imatinib—Somnolence—Valproic Acid—epilepsy syndrome	2.06e-05	0.000146	CcSEcCtD
Imatinib—Immune system disorder—Topiramate—epilepsy syndrome	2.05e-05	0.000146	CcSEcCtD
Imatinib—Nervous system disorder—Pregabalin—epilepsy syndrome	2.05e-05	0.000146	CcSEcCtD
Imatinib—Cough—Gabapentin—epilepsy syndrome	2.05e-05	0.000146	CcSEcCtD
Imatinib—Thrombocytopenia—Pregabalin—epilepsy syndrome	2.05e-05	0.000145	CcSEcCtD
Imatinib—Mediastinal disorder—Topiramate—epilepsy syndrome	2.05e-05	0.000145	CcSEcCtD
Imatinib—Tachycardia—Pregabalin—epilepsy syndrome	2.04e-05	0.000145	CcSEcCtD
Imatinib—Chills—Topiramate—epilepsy syndrome	2.04e-05	0.000145	CcSEcCtD
Imatinib—Dyspepsia—Valproic Acid—epilepsy syndrome	2.04e-05	0.000145	CcSEcCtD
Imatinib—Convulsion—Gabapentin—epilepsy syndrome	2.04e-05	0.000145	CcSEcCtD
Imatinib—Skin disorder—Pregabalin—epilepsy syndrome	2.03e-05	0.000144	CcSEcCtD
Imatinib—Hypertension—Gabapentin—epilepsy syndrome	2.03e-05	0.000144	CcSEcCtD
Imatinib—Hyperhidrosis—Pregabalin—epilepsy syndrome	2.02e-05	0.000144	CcSEcCtD
Imatinib—Vomiting—Clonazepam—epilepsy syndrome	2.02e-05	0.000144	CcSEcCtD
Imatinib—Decreased appetite—Valproic Acid—epilepsy syndrome	2.01e-05	0.000143	CcSEcCtD
Imatinib—Alopecia—Topiramate—epilepsy syndrome	2.01e-05	0.000143	CcSEcCtD
Imatinib—Vomiting—Phenytoin—epilepsy syndrome	2.01e-05	0.000143	CcSEcCtD
Imatinib—Rash—Clonazepam—epilepsy syndrome	2e-05	0.000142	CcSEcCtD
Imatinib—Dermatitis—Clonazepam—epilepsy syndrome	2e-05	0.000142	CcSEcCtD
Imatinib—Myalgia—Gabapentin—epilepsy syndrome	2e-05	0.000142	CcSEcCtD
Imatinib—Chest pain—Gabapentin—epilepsy syndrome	2e-05	0.000142	CcSEcCtD
Imatinib—Arthralgia—Gabapentin—epilepsy syndrome	2e-05	0.000142	CcSEcCtD
Imatinib—Nausea—Felbamate—epilepsy syndrome	2e-05	0.000142	CcSEcCtD
Imatinib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	2e-05	0.000142	CcSEcCtD
Imatinib—Vomiting—Oxcarbazepine—epilepsy syndrome	2e-05	0.000142	CcSEcCtD
Imatinib—Fatigue—Valproic Acid—epilepsy syndrome	1.99e-05	0.000142	CcSEcCtD
Imatinib—Anxiety—Gabapentin—epilepsy syndrome	1.99e-05	0.000142	CcSEcCtD
Imatinib—Anorexia—Pregabalin—epilepsy syndrome	1.99e-05	0.000142	CcSEcCtD
Imatinib—Dizziness—Carbamazepine—epilepsy syndrome	1.99e-05	0.000142	CcSEcCtD
Imatinib—Diarrhoea—Lamotrigine—epilepsy syndrome	1.99e-05	0.000142	CcSEcCtD
Imatinib—Headache—Clonazepam—epilepsy syndrome	1.99e-05	0.000141	CcSEcCtD
Imatinib—Rash—Phenytoin—epilepsy syndrome	1.99e-05	0.000141	CcSEcCtD
Imatinib—Mental disorder—Topiramate—epilepsy syndrome	1.99e-05	0.000141	CcSEcCtD
Imatinib—Dermatitis—Phenytoin—epilepsy syndrome	1.99e-05	0.000141	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	1.99e-05	0.000141	CcSEcCtD
Imatinib—Rash—Oxcarbazepine—epilepsy syndrome	1.98e-05	0.000141	CcSEcCtD
Imatinib—Pain—Valproic Acid—epilepsy syndrome	1.98e-05	0.000141	CcSEcCtD
Imatinib—Constipation—Valproic Acid—epilepsy syndrome	1.98e-05	0.000141	CcSEcCtD
Imatinib—Dermatitis—Oxcarbazepine—epilepsy syndrome	1.98e-05	0.00014	CcSEcCtD
Imatinib—Headache—Phenytoin—epilepsy syndrome	1.98e-05	0.00014	CcSEcCtD
Imatinib—Malnutrition—Topiramate—epilepsy syndrome	1.98e-05	0.00014	CcSEcCtD
Imatinib—Erythema—Topiramate—epilepsy syndrome	1.98e-05	0.00014	CcSEcCtD
Imatinib—Discomfort—Gabapentin—epilepsy syndrome	1.98e-05	0.00014	CcSEcCtD
Imatinib—Headache—Oxcarbazepine—epilepsy syndrome	1.97e-05	0.00014	CcSEcCtD
Imatinib—Nausea—Zonisamide—epilepsy syndrome	1.96e-05	0.000139	CcSEcCtD
Imatinib—Dry mouth—Gabapentin—epilepsy syndrome	1.96e-05	0.000139	CcSEcCtD
Imatinib—Hypotension—Pregabalin—epilepsy syndrome	1.95e-05	0.000139	CcSEcCtD
Imatinib—Flatulence—Topiramate—epilepsy syndrome	1.95e-05	0.000138	CcSEcCtD
Imatinib—Dysgeusia—Topiramate—epilepsy syndrome	1.94e-05	0.000138	CcSEcCtD
Imatinib—Confusional state—Gabapentin—epilepsy syndrome	1.93e-05	0.000137	CcSEcCtD
Imatinib—Dizziness—Lamotrigine—epilepsy syndrome	1.92e-05	0.000137	CcSEcCtD
Imatinib—Oedema—Gabapentin—epilepsy syndrome	1.92e-05	0.000136	CcSEcCtD
Imatinib—Anaphylactic shock—Gabapentin—epilepsy syndrome	1.92e-05	0.000136	CcSEcCtD
Imatinib—Vomiting—Carbamazepine—epilepsy syndrome	1.91e-05	0.000136	CcSEcCtD
Imatinib—Back pain—Topiramate—epilepsy syndrome	1.91e-05	0.000136	CcSEcCtD
Imatinib—Feeling abnormal—Valproic Acid—epilepsy syndrome	1.91e-05	0.000135	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	1.9e-05	0.000135	CcSEcCtD
Imatinib—Infection—Gabapentin—epilepsy syndrome	1.9e-05	0.000135	CcSEcCtD
Imatinib—Muscle spasms—Topiramate—epilepsy syndrome	1.9e-05	0.000135	CcSEcCtD
Imatinib—Rash—Carbamazepine—epilepsy syndrome	1.9e-05	0.000135	CcSEcCtD
Imatinib—Dermatitis—Carbamazepine—epilepsy syndrome	1.9e-05	0.000135	CcSEcCtD
Imatinib—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	1.89e-05	0.000134	CcSEcCtD
Imatinib—Insomnia—Pregabalin—epilepsy syndrome	1.89e-05	0.000134	CcSEcCtD
Imatinib—Nausea—Clonazepam—epilepsy syndrome	1.89e-05	0.000134	CcSEcCtD
Imatinib—Headache—Carbamazepine—epilepsy syndrome	1.89e-05	0.000134	CcSEcCtD
Imatinib—Shock—Gabapentin—epilepsy syndrome	1.89e-05	0.000134	CcSEcCtD
Imatinib—Nervous system disorder—Gabapentin—epilepsy syndrome	1.88e-05	0.000134	CcSEcCtD
Imatinib—Paraesthesia—Pregabalin—epilepsy syndrome	1.88e-05	0.000133	CcSEcCtD
Imatinib—Thrombocytopenia—Gabapentin—epilepsy syndrome	1.88e-05	0.000133	CcSEcCtD
Imatinib—Nausea—Phenytoin—epilepsy syndrome	1.87e-05	0.000133	CcSEcCtD
Imatinib—Tachycardia—Gabapentin—epilepsy syndrome	1.87e-05	0.000133	CcSEcCtD
Imatinib—Dyspnoea—Pregabalin—epilepsy syndrome	1.86e-05	0.000132	CcSEcCtD
Imatinib—Nausea—Oxcarbazepine—epilepsy syndrome	1.86e-05	0.000132	CcSEcCtD
Imatinib—Vision blurred—Topiramate—epilepsy syndrome	1.86e-05	0.000132	CcSEcCtD
Imatinib—Skin disorder—Gabapentin—epilepsy syndrome	1.86e-05	0.000132	CcSEcCtD
Imatinib—Somnolence—Pregabalin—epilepsy syndrome	1.86e-05	0.000132	CcSEcCtD
Imatinib—Hyperhidrosis—Gabapentin—epilepsy syndrome	1.85e-05	0.000132	CcSEcCtD
Imatinib—Tremor—Topiramate—epilepsy syndrome	1.85e-05	0.000132	CcSEcCtD
Imatinib—Vomiting—Lamotrigine—epilepsy syndrome	1.85e-05	0.000132	CcSEcCtD
Imatinib—Urticaria—Valproic Acid—epilepsy syndrome	1.84e-05	0.000131	CcSEcCtD
Imatinib—Rash—Lamotrigine—epilepsy syndrome	1.84e-05	0.00013	CcSEcCtD
Imatinib—Ill-defined disorder—Topiramate—epilepsy syndrome	1.83e-05	0.00013	CcSEcCtD
Imatinib—Dermatitis—Lamotrigine—epilepsy syndrome	1.83e-05	0.00013	CcSEcCtD
Imatinib—Abdominal pain—Valproic Acid—epilepsy syndrome	1.83e-05	0.00013	CcSEcCtD
Imatinib—Body temperature increased—Valproic Acid—epilepsy syndrome	1.83e-05	0.00013	CcSEcCtD
Imatinib—Anorexia—Gabapentin—epilepsy syndrome	1.83e-05	0.00013	CcSEcCtD
Imatinib—Anaemia—Topiramate—epilepsy syndrome	1.83e-05	0.00013	CcSEcCtD
Imatinib—Headache—Lamotrigine—epilepsy syndrome	1.82e-05	0.00013	CcSEcCtD
Imatinib—Decreased appetite—Pregabalin—epilepsy syndrome	1.82e-05	0.000129	CcSEcCtD
Imatinib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	1.81e-05	0.000128	CcSEcCtD
Imatinib—Fatigue—Pregabalin—epilepsy syndrome	1.8e-05	0.000128	CcSEcCtD
Imatinib—Hypotension—Gabapentin—epilepsy syndrome	1.79e-05	0.000127	CcSEcCtD
Imatinib—Nausea—Carbamazepine—epilepsy syndrome	1.79e-05	0.000127	CcSEcCtD
Imatinib—Constipation—Pregabalin—epilepsy syndrome	1.79e-05	0.000127	CcSEcCtD
Imatinib—Pain—Pregabalin—epilepsy syndrome	1.79e-05	0.000127	CcSEcCtD
Imatinib—Malaise—Topiramate—epilepsy syndrome	1.78e-05	0.000127	CcSEcCtD
Imatinib—Vertigo—Topiramate—epilepsy syndrome	1.78e-05	0.000126	CcSEcCtD
Imatinib—Syncope—Topiramate—epilepsy syndrome	1.77e-05	0.000126	CcSEcCtD
Imatinib—Leukopenia—Topiramate—epilepsy syndrome	1.77e-05	0.000126	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	1.75e-05	0.000124	CcSEcCtD
Imatinib—Palpitations—Topiramate—epilepsy syndrome	1.75e-05	0.000124	CcSEcCtD
Imatinib—Loss of consciousness—Topiramate—epilepsy syndrome	1.74e-05	0.000123	CcSEcCtD
Imatinib—Insomnia—Gabapentin—epilepsy syndrome	1.73e-05	0.000123	CcSEcCtD
Imatinib—Nausea—Lamotrigine—epilepsy syndrome	1.73e-05	0.000123	CcSEcCtD
Imatinib—Cough—Topiramate—epilepsy syndrome	1.72e-05	0.000123	CcSEcCtD
Imatinib—Feeling abnormal—Pregabalin—epilepsy syndrome	1.72e-05	0.000122	CcSEcCtD
Imatinib—Paraesthesia—Gabapentin—epilepsy syndrome	1.72e-05	0.000122	CcSEcCtD
Imatinib—Convulsion—Topiramate—epilepsy syndrome	1.71e-05	0.000122	CcSEcCtD
Imatinib—Gastrointestinal pain—Pregabalin—epilepsy syndrome	1.71e-05	0.000122	CcSEcCtD
Imatinib—Dyspnoea—Gabapentin—epilepsy syndrome	1.71e-05	0.000121	CcSEcCtD
Imatinib—Hypertension—Topiramate—epilepsy syndrome	1.71e-05	0.000121	CcSEcCtD
Imatinib—Somnolence—Gabapentin—epilepsy syndrome	1.7e-05	0.000121	CcSEcCtD
Imatinib—Hypersensitivity—Valproic Acid—epilepsy syndrome	1.7e-05	0.000121	CcSEcCtD
Imatinib—Dyspepsia—Gabapentin—epilepsy syndrome	1.69e-05	0.00012	CcSEcCtD
Imatinib—Chest pain—Topiramate—epilepsy syndrome	1.68e-05	0.00012	CcSEcCtD
Imatinib—Arthralgia—Topiramate—epilepsy syndrome	1.68e-05	0.00012	CcSEcCtD
Imatinib—Myalgia—Topiramate—epilepsy syndrome	1.68e-05	0.00012	CcSEcCtD
Imatinib—Anxiety—Topiramate—epilepsy syndrome	1.68e-05	0.000119	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	1.67e-05	0.000119	CcSEcCtD
Imatinib—Decreased appetite—Gabapentin—epilepsy syndrome	1.67e-05	0.000118	CcSEcCtD
Imatinib—Discomfort—Topiramate—epilepsy syndrome	1.66e-05	0.000118	CcSEcCtD
Imatinib—Urticaria—Pregabalin—epilepsy syndrome	1.66e-05	0.000118	CcSEcCtD
Imatinib—Asthenia—Valproic Acid—epilepsy syndrome	1.66e-05	0.000118	CcSEcCtD
Imatinib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	1.66e-05	0.000118	CcSEcCtD
Imatinib—Fatigue—Gabapentin—epilepsy syndrome	1.65e-05	0.000117	CcSEcCtD
Imatinib—Abdominal pain—Pregabalin—epilepsy syndrome	1.65e-05	0.000117	CcSEcCtD
Imatinib—Body temperature increased—Pregabalin—epilepsy syndrome	1.65e-05	0.000117	CcSEcCtD
Imatinib—Dry mouth—Topiramate—epilepsy syndrome	1.65e-05	0.000117	CcSEcCtD
Imatinib—Pain—Gabapentin—epilepsy syndrome	1.64e-05	0.000117	CcSEcCtD
Imatinib—Constipation—Gabapentin—epilepsy syndrome	1.64e-05	0.000117	CcSEcCtD
Imatinib—Pruritus—Valproic Acid—epilepsy syndrome	1.64e-05	0.000116	CcSEcCtD
Imatinib—Confusional state—Topiramate—epilepsy syndrome	1.63e-05	0.000116	CcSEcCtD
Imatinib—Oedema—Topiramate—epilepsy syndrome	1.61e-05	0.000115	CcSEcCtD
Imatinib—Infection—Topiramate—epilepsy syndrome	1.6e-05	0.000114	CcSEcCtD
Imatinib—Shock—Topiramate—epilepsy syndrome	1.59e-05	0.000113	CcSEcCtD
Imatinib—Diarrhoea—Valproic Acid—epilepsy syndrome	1.58e-05	0.000112	CcSEcCtD
Imatinib—Nervous system disorder—Topiramate—epilepsy syndrome	1.58e-05	0.000112	CcSEcCtD
Imatinib—Feeling abnormal—Gabapentin—epilepsy syndrome	1.58e-05	0.000112	CcSEcCtD
Imatinib—Thrombocytopenia—Topiramate—epilepsy syndrome	1.58e-05	0.000112	CcSEcCtD
Imatinib—Tachycardia—Topiramate—epilepsy syndrome	1.57e-05	0.000112	CcSEcCtD
Imatinib—Gastrointestinal pain—Gabapentin—epilepsy syndrome	1.57e-05	0.000111	CcSEcCtD
Imatinib—Skin disorder—Topiramate—epilepsy syndrome	1.57e-05	0.000111	CcSEcCtD
Imatinib—Hyperhidrosis—Topiramate—epilepsy syndrome	1.56e-05	0.000111	CcSEcCtD
Imatinib—Hypersensitivity—Pregabalin—epilepsy syndrome	1.54e-05	0.000109	CcSEcCtD
Imatinib—Anorexia—Topiramate—epilepsy syndrome	1.54e-05	0.000109	CcSEcCtD
Imatinib—Dizziness—Valproic Acid—epilepsy syndrome	1.53e-05	0.000109	CcSEcCtD
Imatinib—Urticaria—Gabapentin—epilepsy syndrome	1.52e-05	0.000108	CcSEcCtD
Imatinib—Abdominal pain—Gabapentin—epilepsy syndrome	1.52e-05	0.000108	CcSEcCtD
Imatinib—Body temperature increased—Gabapentin—epilepsy syndrome	1.52e-05	0.000108	CcSEcCtD
Imatinib—Hypotension—Topiramate—epilepsy syndrome	1.51e-05	0.000107	CcSEcCtD
Imatinib—Asthenia—Pregabalin—epilepsy syndrome	1.5e-05	0.000107	CcSEcCtD
Imatinib—Pruritus—Pregabalin—epilepsy syndrome	1.48e-05	0.000105	CcSEcCtD
Imatinib—Vomiting—Valproic Acid—epilepsy syndrome	1.47e-05	0.000105	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	1.47e-05	0.000104	CcSEcCtD
Imatinib—Insomnia—Topiramate—epilepsy syndrome	1.46e-05	0.000104	CcSEcCtD
Imatinib—Rash—Valproic Acid—epilepsy syndrome	1.46e-05	0.000104	CcSEcCtD
Imatinib—Dermatitis—Valproic Acid—epilepsy syndrome	1.46e-05	0.000104	CcSEcCtD
Imatinib—Headache—Valproic Acid—epilepsy syndrome	1.45e-05	0.000103	CcSEcCtD
Imatinib—Paraesthesia—Topiramate—epilepsy syndrome	1.45e-05	0.000103	CcSEcCtD
Imatinib—Dyspnoea—Topiramate—epilepsy syndrome	1.44e-05	0.000102	CcSEcCtD
Imatinib—Somnolence—Topiramate—epilepsy syndrome	1.43e-05	0.000102	CcSEcCtD
Imatinib—Diarrhoea—Pregabalin—epilepsy syndrome	1.43e-05	0.000102	CcSEcCtD
Imatinib—Dyspepsia—Topiramate—epilepsy syndrome	1.42e-05	0.000101	CcSEcCtD
Imatinib—Hypersensitivity—Gabapentin—epilepsy syndrome	1.41e-05	0.0001	CcSEcCtD
Imatinib—Decreased appetite—Topiramate—epilepsy syndrome	1.4e-05	9.97e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	1.39e-05	9.9e-05	CcSEcCtD
Imatinib—Fatigue—Topiramate—epilepsy syndrome	1.39e-05	9.88e-05	CcSEcCtD
Imatinib—Dizziness—Pregabalin—epilepsy syndrome	1.38e-05	9.83e-05	CcSEcCtD
Imatinib—Constipation—Topiramate—epilepsy syndrome	1.38e-05	9.8e-05	CcSEcCtD
Imatinib—Pain—Topiramate—epilepsy syndrome	1.38e-05	9.8e-05	CcSEcCtD
Imatinib—Asthenia—Gabapentin—epilepsy syndrome	1.38e-05	9.78e-05	CcSEcCtD
Imatinib—Nausea—Valproic Acid—epilepsy syndrome	1.37e-05	9.76e-05	CcSEcCtD
Imatinib—Pruritus—Gabapentin—epilepsy syndrome	1.36e-05	9.64e-05	CcSEcCtD
Imatinib—Vomiting—Pregabalin—epilepsy syndrome	1.33e-05	9.45e-05	CcSEcCtD
Imatinib—Feeling abnormal—Topiramate—epilepsy syndrome	1.33e-05	9.45e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Topiramate—epilepsy syndrome	1.32e-05	9.37e-05	CcSEcCtD
Imatinib—Rash—Pregabalin—epilepsy syndrome	1.32e-05	9.37e-05	CcSEcCtD
Imatinib—Dermatitis—Pregabalin—epilepsy syndrome	1.32e-05	9.36e-05	CcSEcCtD
Imatinib—Diarrhoea—Gabapentin—epilepsy syndrome	1.31e-05	9.32e-05	CcSEcCtD
Imatinib—Headache—Pregabalin—epilepsy syndrome	1.31e-05	9.31e-05	CcSEcCtD
Imatinib—Urticaria—Topiramate—epilepsy syndrome	1.28e-05	9.11e-05	CcSEcCtD
Imatinib—Abdominal pain—Topiramate—epilepsy syndrome	1.28e-05	9.06e-05	CcSEcCtD
Imatinib—Body temperature increased—Topiramate—epilepsy syndrome	1.28e-05	9.06e-05	CcSEcCtD
Imatinib—Dizziness—Gabapentin—epilepsy syndrome	1.27e-05	9.01e-05	CcSEcCtD
Imatinib—Nausea—Pregabalin—epilepsy syndrome	1.24e-05	8.83e-05	CcSEcCtD
Imatinib—Vomiting—Gabapentin—epilepsy syndrome	1.22e-05	8.66e-05	CcSEcCtD
Imatinib—Rash—Gabapentin—epilepsy syndrome	1.21e-05	8.59e-05	CcSEcCtD
Imatinib—Dermatitis—Gabapentin—epilepsy syndrome	1.21e-05	8.58e-05	CcSEcCtD
Imatinib—Headache—Gabapentin—epilepsy syndrome	1.2e-05	8.54e-05	CcSEcCtD
Imatinib—Hypersensitivity—Topiramate—epilepsy syndrome	1.19e-05	8.45e-05	CcSEcCtD
Imatinib—Asthenia—Topiramate—epilepsy syndrome	1.16e-05	8.22e-05	CcSEcCtD
Imatinib—Pruritus—Topiramate—epilepsy syndrome	1.14e-05	8.11e-05	CcSEcCtD
Imatinib—Nausea—Gabapentin—epilepsy syndrome	1.14e-05	8.09e-05	CcSEcCtD
Imatinib—Diarrhoea—Topiramate—epilepsy syndrome	1.1e-05	7.84e-05	CcSEcCtD
Imatinib—Dizziness—Topiramate—epilepsy syndrome	1.07e-05	7.58e-05	CcSEcCtD
Imatinib—Vomiting—Topiramate—epilepsy syndrome	1.03e-05	7.29e-05	CcSEcCtD
Imatinib—Rash—Topiramate—epilepsy syndrome	1.02e-05	7.23e-05	CcSEcCtD
Imatinib—Dermatitis—Topiramate—epilepsy syndrome	1.02e-05	7.22e-05	CcSEcCtD
Imatinib—Headache—Topiramate—epilepsy syndrome	1.01e-05	7.18e-05	CcSEcCtD
Imatinib—Nausea—Topiramate—epilepsy syndrome	9.58e-06	6.81e-05	CcSEcCtD
Imatinib—LCK—Signaling Pathways—YWHAZ—epilepsy syndrome	1.07e-06	1.15e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—AKT1—epilepsy syndrome	1.06e-06	1.15e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP11A1—epilepsy syndrome	1.06e-06	1.15e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AGT—epilepsy syndrome	1.06e-06	1.15e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—SLC2A1—epilepsy syndrome	1.06e-06	1.14e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NGF—epilepsy syndrome	1.06e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.05e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.05e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP2D6—epilepsy syndrome	1.05e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	1.05e-06	1.13e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PLCB1—epilepsy syndrome	1.05e-06	1.13e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—TH—epilepsy syndrome	1.04e-06	1.13e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—BCL2—epilepsy syndrome	1.04e-06	1.13e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—APOE—epilepsy syndrome	1.04e-06	1.12e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—AKT1—epilepsy syndrome	1.04e-06	1.12e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—FGF2—epilepsy syndrome	1.04e-06	1.12e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—SRC—epilepsy syndrome	1.03e-06	1.12e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.03e-06	1.11e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCR5—epilepsy syndrome	1.03e-06	1.11e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	1.03e-06	1.11e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—SRC—epilepsy syndrome	1.02e-06	1.1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—AKT1—epilepsy syndrome	1.02e-06	1.1e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AGT—epilepsy syndrome	1.02e-06	1.1e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—RELA—epilepsy syndrome	1.02e-06	1.1e-05	CbGpPWpGaD
Imatinib—LCK—Disease—FGF2—epilepsy syndrome	1.01e-06	1.09e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—HMOX1—epilepsy syndrome	1.01e-06	1.09e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	1.01e-06	1.09e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—VEGFA—epilepsy syndrome	1.01e-06	1.09e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HTR2A—epilepsy syndrome	1e-06	1.09e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ADRA2A—epilepsy syndrome	1e-06	1.08e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—POMC—epilepsy syndrome	1e-06	1.08e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MTOR—epilepsy syndrome	9.99e-07	1.08e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—APOE—epilepsy syndrome	9.98e-07	1.08e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CAT—epilepsy syndrome	9.98e-07	1.08e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—SRC—epilepsy syndrome	9.98e-07	1.08e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—BCHE—epilepsy syndrome	9.96e-07	1.08e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—FGF2—epilepsy syndrome	9.81e-07	1.06e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AQP1—epilepsy syndrome	9.81e-07	1.06e-05	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	9.78e-07	1.06e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCL2—epilepsy syndrome	9.78e-07	1.06e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	9.77e-07	1.05e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—BCHE—epilepsy syndrome	9.73e-07	1.05e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—SRC—epilepsy syndrome	9.72e-07	1.05e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ABCB1—epilepsy syndrome	9.71e-07	1.05e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—RELA—epilepsy syndrome	9.62e-07	1.04e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	9.61e-07	1.04e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP2D6—epilepsy syndrome	9.58e-07	1.04e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TSC2—epilepsy syndrome	9.54e-07	1.03e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AGT—epilepsy syndrome	9.53e-07	1.03e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—SLC2A1—epilepsy syndrome	9.51e-07	1.03e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—AKT1—epilepsy syndrome	9.49e-07	1.02e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MTOR—epilepsy syndrome	9.44e-07	1.02e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PLCB1—epilepsy syndrome	9.4e-07	1.02e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ABCG2—epilepsy syndrome	9.37e-07	1.01e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—TH—epilepsy syndrome	9.37e-07	1.01e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—APOE—epilepsy syndrome	9.34e-07	1.01e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—POMC—epilepsy syndrome	9.3e-07	1e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	9.28e-07	1e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MTOR—epilepsy syndrome	9.22e-07	9.96e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	9.22e-07	9.96e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—POMC—epilepsy syndrome	9.21e-07	9.95e-06	CbGpPWpGaD
Imatinib—PDGFRB—Disease—SRC—epilepsy syndrome	9.21e-07	9.95e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—IL1B—epilepsy syndrome	9.21e-07	9.95e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	9.2e-07	9.94e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—POMC—epilepsy syndrome	9.2e-07	9.94e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PLCB1—epilepsy syndrome	9.18e-07	9.91e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—BCHE—epilepsy syndrome	9.16e-07	9.9e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KDR—epilepsy syndrome	9.15e-07	9.89e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—TH—epilepsy syndrome	9.14e-07	9.88e-06	CbGpPWpGaD
Imatinib—LCK—Disease—PTGS2—epilepsy syndrome	9.14e-07	9.87e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP2C19—epilepsy syndrome	9.13e-07	9.86e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—SRC—epilepsy syndrome	9.13e-07	9.86e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	9.12e-07	9.86e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—RELA—epilepsy syndrome	9.11e-07	9.84e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—BCHE—epilepsy syndrome	9.09e-07	9.81e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP11A1—epilepsy syndrome	9.07e-07	9.8e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GPX1—epilepsy syndrome	9.02e-07	9.75e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	9.01e-07	9.73e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MTOR—epilepsy syndrome	8.93e-07	9.65e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—POMC—epilepsy syndrome	8.93e-07	9.65e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—JUN—epilepsy syndrome	8.93e-07	9.64e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—VEGFA—epilepsy syndrome	8.89e-07	9.6e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	8.87e-07	9.58e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	8.87e-07	9.58e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—FGF2—epilepsy syndrome	8.84e-07	9.55e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PRKCB—epilepsy syndrome	8.81e-07	9.52e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6ST—epilepsy syndrome	8.77e-07	9.48e-06	CbGpPWpGaD
Imatinib—CA2—Metabolism—AKT1—epilepsy syndrome	8.75e-07	9.45e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	8.74e-07	9.44e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—HMOX1—epilepsy syndrome	8.71e-07	9.41e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CASP3—epilepsy syndrome	8.68e-07	9.38e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	8.67e-07	9.36e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	8.65e-07	9.34e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TH—epilepsy syndrome	8.62e-07	9.31e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—CAT—epilepsy syndrome	8.59e-07	9.28e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—POMC—epilepsy syndrome	8.57e-07	9.26e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	8.57e-07	9.26e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TH—epilepsy syndrome	8.54e-07	9.23e-06	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—AKT1—epilepsy syndrome	8.54e-07	9.23e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—ALB—epilepsy syndrome	8.48e-07	9.16e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—JUN—epilepsy syndrome	8.43e-07	9.11e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	8.41e-07	9.08e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—ALB—epilepsy syndrome	8.4e-07	9.07e-06	CbGpPWpGaD
Imatinib—CA1—Metabolism—AKT1—epilepsy syndrome	8.39e-07	9.06e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—ALB—epilepsy syndrome	8.39e-07	9.06e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—ABCB1—epilepsy syndrome	8.36e-07	9.03e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CASP3—epilepsy syndrome	8.22e-07	8.88e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	8.21e-07	8.87e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RELA—epilepsy syndrome	8.21e-07	8.87e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP9—epilepsy syndrome	8.2e-07	8.86e-06	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—AKT1—epilepsy syndrome	8.2e-07	8.86e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP2D6—epilepsy syndrome	8.19e-07	8.85e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ALB—epilepsy syndrome	8.14e-07	8.8e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MTOR—epilepsy syndrome	8.05e-07	8.69e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—POMC—epilepsy syndrome	8.02e-07	8.67e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—SRC—epilepsy syndrome	8.01e-07	8.65e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—JUN—epilepsy syndrome	7.98e-07	8.62e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AGT—epilepsy syndrome	7.91e-07	8.55e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCL2—epilepsy syndrome	7.85e-07	8.48e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—HMOX1—epilepsy syndrome	7.82e-07	8.45e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ALB—epilepsy syndrome	7.82e-07	8.45e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ADRA2A—epilepsy syndrome	7.8e-07	8.42e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—GPX1—epilepsy syndrome	7.77e-07	8.4e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—epilepsy syndrome	7.77e-07	8.39e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—BCHE—epilepsy syndrome	7.76e-07	8.39e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—APOE—epilepsy syndrome	7.75e-07	8.38e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CAT—epilepsy syndrome	7.71e-07	8.33e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—HMOX1—epilepsy syndrome	7.63e-07	8.24e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SRC—epilepsy syndrome	7.56e-07	8.17e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CAT—epilepsy syndrome	7.53e-07	8.13e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ABCB1—epilepsy syndrome	7.5e-07	8.11e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—epilepsy syndrome	7.41e-07	8.01e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SLC2A1—epilepsy syndrome	7.41e-07	8e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CASP3—epilepsy syndrome	7.4e-07	8e-06	CbGpPWpGaD
Imatinib—LCK—Disease—SRC—epilepsy syndrome	7.39e-07	7.98e-06	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—epilepsy syndrome	7.37e-07	7.97e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—epilepsy syndrome	7.37e-07	7.96e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—epilepsy syndrome	7.35e-07	7.94e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—epilepsy syndrome	7.34e-07	7.93e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PLCB1—epilepsy syndrome	7.33e-07	7.91e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TH—epilepsy syndrome	7.3e-07	7.89e-06	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—epilepsy syndrome	7.27e-07	7.85e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	7.23e-07	7.81e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	7.19e-07	7.77e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—JUN—epilepsy syndrome	7.19e-07	7.77e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	7.19e-07	7.76e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SRC—epilepsy syndrome	7.16e-07	7.73e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	7.13e-07	7.7e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—epilepsy syndrome	7.12e-07	7.7e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CAT—epilepsy syndrome	7.1e-07	7.67e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FGF2—epilepsy syndrome	7.1e-07	7.66e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	7.05e-07	7.61e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CAT—epilepsy syndrome	7.03e-07	7.6e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	7e-07	7.57e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—epilepsy syndrome	7e-07	7.56e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GPX1—epilepsy syndrome	6.98e-07	7.54e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—epilepsy syndrome	6.97e-07	7.53e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	6.9e-07	7.46e-06	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—epilepsy syndrome	6.88e-07	7.43e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	6.84e-07	7.39e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—epilepsy syndrome	6.84e-07	7.39e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—AGT—epilepsy syndrome	6.81e-07	7.36e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GPX1—epilepsy syndrome	6.81e-07	7.36e-06	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—epilepsy syndrome	6.71e-07	7.25e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—APOE—epilepsy syndrome	6.68e-07	7.21e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—POMC—epilepsy syndrome	6.66e-07	7.2e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RELA—epilepsy syndrome	6.59e-07	7.12e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MTOR—epilepsy syndrome	6.46e-07	6.98e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SRC—epilepsy syndrome	6.45e-07	6.97e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GPX1—epilepsy syndrome	6.42e-07	6.93e-06	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—epilepsy syndrome	6.41e-07	6.93e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GPX1—epilepsy syndrome	6.36e-07	6.87e-06	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—epilepsy syndrome	6.35e-07	6.86e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	6.32e-07	6.83e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—epilepsy syndrome	6.28e-07	6.79e-06	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—epilepsy syndrome	6.2e-07	6.7e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AGT—epilepsy syndrome	6.12e-07	6.61e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HMOX1—epilepsy syndrome	6.09e-07	6.58e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—epilepsy syndrome	6.07e-07	6.56e-06	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—epilepsy syndrome	6.04e-07	6.53e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	6.02e-07	6.5e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CAT—epilepsy syndrome	6.01e-07	6.49e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—APOE—epilepsy syndrome	5.99e-07	6.48e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	5.99e-07	6.47e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AGT—epilepsy syndrome	5.97e-07	6.45e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—epilepsy syndrome	5.94e-07	6.42e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOE—epilepsy syndrome	5.85e-07	6.32e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ABCB1—epilepsy syndrome	5.85e-07	6.32e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—JUN—epilepsy syndrome	5.77e-07	6.23e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—POMC—epilepsy syndrome	5.74e-07	6.2e-06	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—epilepsy syndrome	5.72e-07	6.18e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	5.72e-07	6.17e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—epilepsy syndrome	5.67e-07	6.13e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	5.65e-07	6.11e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TH—epilepsy syndrome	5.63e-07	6.09e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AGT—epilepsy syndrome	5.63e-07	6.08e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—epilepsy syndrome	5.61e-07	6.06e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AGT—epilepsy syndrome	5.58e-07	6.03e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOE—epilepsy syndrome	5.51e-07	5.96e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOE—epilepsy syndrome	5.47e-07	5.9e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GPX1—epilepsy syndrome	5.44e-07	5.87e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—epilepsy syndrome	5.31e-07	5.74e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SRC—epilepsy syndrome	5.18e-07	5.59e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—POMC—epilepsy syndrome	5.15e-07	5.56e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—epilepsy syndrome	5.04e-07	5.45e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—POMC—epilepsy syndrome	5.03e-07	5.43e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—epilepsy syndrome	4.98e-07	5.37e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AGT—epilepsy syndrome	4.77e-07	5.15e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—POMC—epilepsy syndrome	4.74e-07	5.12e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	4.7e-07	5.08e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—epilepsy syndrome	4.7e-07	5.08e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—POMC—epilepsy syndrome	4.7e-07	5.07e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—epilepsy syndrome	4.69e-07	5.07e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOE—epilepsy syndrome	4.67e-07	5.05e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CAT—epilepsy syndrome	4.64e-07	5.01e-06	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—epilepsy syndrome	4.59e-07	4.96e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—epilepsy syndrome	4.58e-07	4.95e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—epilepsy syndrome	4.58e-07	4.94e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	4.51e-07	4.88e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—epilepsy syndrome	4.45e-07	4.81e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—epilepsy syndrome	4.32e-07	4.66e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—epilepsy syndrome	4.28e-07	4.62e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	4.2e-07	4.53e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—epilepsy syndrome	4.11e-07	4.44e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—POMC—epilepsy syndrome	4.01e-07	4.33e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—epilepsy syndrome	4.01e-07	4.33e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—epilepsy syndrome	4.01e-07	4.33e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	3.78e-07	4.08e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	3.74e-07	4.05e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—epilepsy syndrome	3.73e-07	4.03e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—epilepsy syndrome	3.69e-07	3.99e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—epilepsy syndrome	3.69e-07	3.98e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AGT—epilepsy syndrome	3.68e-07	3.97e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—epilepsy syndrome	3.66e-07	3.95e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOE—epilepsy syndrome	3.6e-07	3.89e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—epilepsy syndrome	3.58e-07	3.87e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—epilepsy syndrome	3.44e-07	3.71e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—epilepsy syndrome	3.22e-07	3.47e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—epilepsy syndrome	3.2e-07	3.46e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—POMC—epilepsy syndrome	3.1e-07	3.35e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—epilepsy syndrome	2.82e-07	3.05e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—epilepsy syndrome	2.67e-07	2.88e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	2.47e-07	2.67e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—epilepsy syndrome	2.3e-07	2.48e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—epilepsy syndrome	2.06e-07	2.23e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—epilepsy syndrome	2.01e-07	2.18e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—epilepsy syndrome	1.9e-07	2.05e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—epilepsy syndrome	1.88e-07	2.03e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—epilepsy syndrome	1.61e-07	1.74e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	1.24e-07	1.34e-06	CbGpPWpGaD
